The Center for Medicine in the Public Interest (CMPI) has initiated a research program to study the treatment preferences of patients with Idiopathic pulmonary fibrosis (IPF). The project is supported by Intermune, a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. Dr. John F P Bridges PhD, an Associate Professor at the Johns Hopkins Bloomberg School of Public Health and Senior Fellow at CMPI, will serve as the principal investigator of this project. The project will apply the principles of community-based participatory medicine to engage patients, family members, providers and other stakeholder in the design and pilot of a survey instrument to measure the stated-preferences of patients of with IPF for the potential benefits and risk of therapy. A geographically diverse sample of patients with IPF will be then recruited through clinics and advocacy groups to complete the survey. Analysis will use state-of-the-art methods to estimate preferences and results will be disseminated widely.
Patient-Centric & Prospective Medicine Project
RECENT NEWS
New JCI Viewpoint: FDA Must Rethink How It Evaluates Precision Medicines for Rare Diseases
Authors argue that rare disease innovation requires learning more from fewer patients—not enrolling more patients... Read more
Qualifying Single-Source Drug Policy, Medicare Price Negotiation, and the Incentives for Meaningful Post-Approval Innovation
CMS should demand evidence from manufacturers and be prepared to defend its own assumptions about innovation. Its next st... Read more
Troubling Trends: Systemic Practices in Texas' Non-Profit Hospitals That Inflate Health Care Costs
Texas has an opportunity to lead rather than react. Better measurement would strengthen public confidence without diminis... Read more